Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Business Wire
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarterSage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S.Topline data from the DIMENSION Study in Huntington’s Disease (HD) expected late 2024Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024.“We are committed to harnessing the full potential of ZURZUVAE as a transformative treatment for women with postpartum depression. Our encouraging third quarter results, highlighted by continued growth in revenue and shipments, brings us one step closer to our goal of establishing ZURZUVAE as the standard of care to help more women su
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Stifel Nicolaus from $10.00 to $6.00. They now have a "hold" rating on the stock.MarketBeat
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceBusiness Wire
- Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]Yahoo! Finance
SAGE
Earnings
- 10/29/24 - Miss
SAGE
Sec Filings
- 12/13/24 - Form 144
- 11/26/24 - Form 8-K
- 11/20/24 - Form 8-K
- SAGE's page on the SEC website